Status: Not yet recruiting
Study on the Treatment of Double/Triple-hit DLBCL With Chidamide and Lisaftoclax in Combination With Pola-R-CHP
This is an open-label, multicenter clinical study for patients aged 65 and above with double/triple-hit diffuse large B-cell lymphoma who are not suitable for transplantation. The study employs a 6-cycle CL-Pola-R-CHP regimen, with cycles repeated every 21 days.
Participants needed: 28
Trial details
Phase: Phase 2Age: 65+Biological sex: AllType: InterventionalSponsor: Ruijin HospitalUpdated: Apr 27, 2026
Eligibility criteria
Histopathological diagnosis confirmed as diffuse large B-cell lymphoma, with CD2... [+7]
There is a history of other malignant tumors, excluding basal cell carcinoma and... [+9]